These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36431337)

  • 1. Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study.
    Xie S; Yu Y; Liu Y; Zhang S; Yuan S; Fan K; Tang B; Zhou Q; Sun Y; Liu R; Cao D; Chen Y; Wang Y; Liu G; Ma H; Tao C; Zeng L; Zhong L
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study.
    Koc H; Hoser H; Akdag Y; Kendir C; Ersoy FF
    Int Urol Nephrol; 2019 Jul; 51(7):1261-1270. PubMed ID: 31161518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ; González EA; Gellens M; Hamm LL; Abboud H; Lindberg J
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits.
    Chen X; Zhao F; Pan WJ; Di JM; Xie WN; Yuan L; Liu Z
    World J Clin Cases; 2021 Nov; 9(33):10172-10179. PubMed ID: 34904087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
    Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
    Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
    Llach F; Keshav G; Goldblat MV; Lindberg JS; Sadler R; Delmez J; Arruda J; Lau A; Slatopolsky E
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D; Acharya M; Qiu P; Abboud H; Batlle D; Rosansky S; Fadem S; Levine B; Williams L; Andress DL; Sprague SM
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
    Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
    Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison.
    Zawierucha J; Malyszko J; Malyszko JS; Prystacki T; Marcinkowski WP; Dryl-Rydzynska T
    Front Endocrinol (Lausanne); 2019; 10():40. PubMed ID: 30804890
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
    Staniforth ME; Cheng SC; Coyne DW
    Clin Nephrol; 2005 Jun; 63(6):454-60. PubMed ID: 15960147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis.
    Wang N; Xie Y; Jiang G
    Ann Palliat Med; 2022 Jan; 11(1):225-239. PubMed ID: 35144414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.